FFP 104

Drug Profile

FFP 104

Alternative Names: FFP104

Latest Information Update: 08 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FF Pharma
  • Class Antifibrotics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Primary biliary cirrhosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Jan 2016 Phase-II clinical trials in Crohn's disease in Netherlands, Belgium (IV) (NCT02465944)
  • 13 Jun 2015 FF Pharmaceuticals plans a phase I/II in Crohn's disease in Netherlands (NCT02465944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top